Two older women outside hugging and smiling.
Explore Our Clinical Trials
Explore Our Clinical Trials

A New Approach to Treating Inflammatory & Autoimmune Conditions 

Your immune system keeps you safe from things that could make you sick, like bacteria and viruses. But sometimes, the immune system doesn’t work the way it should. It can overreact in unhelpful ways or accidentally attack your body, causing inflammation. When your immune system responds in this way, you may have an inflammatory or autoimmune condition.

Some immune system conditions are long-term, also known as chronic, and may affect your daily life in ways others can’t always see. But with the right treatment and support, many people find ways to manage their condition and feel more in control. Kymera is dedicated to creating new oral medicines (treatments taken by mouth) to help people living with these conditions feel better and live life more fully.

Atopic Dermatitis (Eczema) 
Atopic dermatitis, also known as eczema, is a chronic, inflammatory skin condition that can cause painful, dry, itchy patches of skin. About 1 in 38 people around the world have atopic dermatitis.1
Asthma
Asthma is a chronic, inflammatory lung disease that makes it hard to breathe and can be life threatening. Symptoms can include shortness of breath and coughing. About 1 in 30 people around the world have asthma.2
A person with a pill in their hand.

Researching an Easy Pill for a Tough Problem

Living with an inflammatory or autoimmune condition can be hard — but treatment shouldn’t be. Kymera is doing research to create a pill to target the root cause of immune-related problems in conditions including atopic dermatitis (eczema) and asthma. Our goal is to develop treatments that are both effective and easy to use — so you can live each day with more comfort, confidence and control.

Working with Your Body to Fight Disease

Proteins are the building blocks of your body that help you function and stay healthy. But they can sometimes cause problems and act in harmful ways in your immune system. Your body has a natural system for removing proteins that are no longer needed. Kymera’s medicines are designed to use this natural system to remove unhelpful proteins that might be making your inflammation worse. This approach is called targeted protein degradation, or TPD.

A man and woman spending time together outside by a stream.

Kymera’s Clinical Trials

A clinical trial is a research study to test if new medicines are safe and effective. Kymera is conducting clinical trials to test a new investigational oral therapy for immune system conditions including atopic dermatitis (eczema) and asthma. Talk with your doctor about whether a clinical trial is right for you. Learn more about Kymera’s ongoing trials below.

The safety and efficacy of these investigational agents have not been established. These agents are not approved by any regulatory body for any indication.

KT-621 is an investigational oral degrader in development for the treatment of immunological and inflammatory diseases

RECRUITING
BROADEN2 Phase 2b in Atopic Dermatitis

The KT-621 BROADEN2 Phase 2b randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial is evaluating the efficacy, safety, and tolerability of orally administered KT-621 in adult patients with moderate to severe atopic dermatitis (AD), a common form of eczema.

RECRUITING
BREADTH Phase 2b in Asthma

The KT-621 BREADTH Phase 2b randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial is evaluating the efficacy, safety, and tolerability of orally administered KT-621 in adult patients with moderate to severe eosinophilic asthma.

ACTIVE, NOT RECRUITING
BroADen Phase 1b in Atopic Dermatitis

The KT-621 BroADen Phase 1b single-arm, open label trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult patients with moderate to severe atopic dermatitis (AD), a common form of eczema.

COMPLETED
Phase 1a in Healthy Volunteers

The Phase 1 trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered KT-621 in healthy volunteers. The study includes double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) cohorts.

Kymera’s investigational drugs are currently at a stage in development where we are focused on enrolling patients in our clinical trials and continuing to learn more about our investigational drugs’ safety and efficacy. At this time, Kymera is not able to make expanded access available to its investigational drugs. For more information, please read our full expanded access policy.

References

  1. A study about how many people around the world have atopic dermatitis. Br J Dermatol. 2024;190(1):e6. doi:10.1093/bjd/ljad462

  2. The Global Asthma Network. The Global Asthma Report 2022. Int J Tuberc Lung Dis. 2022;26(1):1-104. doi:10.5588/ijtld.22.1010